September 2025
1. HOGWOOD AC, Golino M, Moroni F, Canada JM, et al
   The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials.
   J Cardiovasc Pharmacol. 2025 Sep 9. doi: 10.1097/FJC.0000000000001756.
   

   >> Share

   
   August 2025
2. GALLUZZO A, Bertaina M, Vishram-Nielsen JKK, Camilli M, et al
   Current Practices and Perspectives on the Use of Intravenous Vasodilators in Acute Heart Failure: An International Survey.
   J Cardiovasc Pharmacol. 2025 Aug 20. doi: 10.1097/FJC.0000000000001753.
   

   >> Share

   
   
3. WEN S, Liu X, Liu L, Hu Y, et al
   Landscape of Berberine Targets: A Potential Pharmacological Insight for Heart failure Treatment.
   J Cardiovasc Pharmacol. 2025 Aug 20. doi: 10.1097/FJC.0000000000001750.
   

   >> Share

   
   June 2025
4. ABBATE A
   Heart failure with preserved ejection fraction: how far we've come - a brief report from two outstanding educational events.
   J Cardiovasc Pharmacol. 2025 Jun 27. doi: 10.1097/FJC.0000000000001733.
   

   >> Share

   
   
5. WU Y, Song M, Chen W, Liang F, et al
   miR-132 inhibition improves cardiac remodeling and function in a two-hit mouse model of heart failure with a preserved ejection fraction.
   J Cardiovasc Pharmacol. 2025 Jun 18. doi: 10.1097/FJC.0000000000001729.
   

   >> Share

   
   May 2025
6. ZHANG J, Chen X, Wan C
   Aerobic exercise rehabilitation training alleviates skeletal muscle atrophy caused by heart failure in mice through the SIRT1/PGC-1alpha pathway.
   J Cardiovasc Pharmacol. 2025 May 28. doi: 10.1097/FJC.0000000000001722.
   

   >> Share

   
   
7. YAMASHITA I, Fujisaki T, Romeo FJ, Sueta D, et al
   Comparing the Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors Among Nonolder and Older Patients: A Systematic Review and Meta-Analysis.
   J Cardiovasc Pharmacol. 2025;85:329-337.
   

   >> Share

   
   April 2025
8. CHEN C, Qin X, Cao Y, Qing L, et al
   Flavin adenine dinucleotide ameliorates pressure overload-induced heart failure by activating the short-chain acyl-CoA dehydrogenase.
   J Cardiovasc Pharmacol. 2025 Apr 8. doi: 10.1097/FJC.0000000000001698.
   

   >> Share

   
   March 2025
9. BIONDI-ZOCCAI G, Galli M, Booz GW
   Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction, Erratum.
   J Cardiovasc Pharmacol. 2025;85:238.
   

   >> Share

   
   February 2025
10. GALATI G, Germanova O
    Mineralocorticoid receptor antagonists in end-stage renal disease under renal replacement therapies: bridging the gap between cardiovascular and systemic benefit, from heart failure to myocardial infarction.
    J Cardiovasc Pharmacol. 2025 Feb 6. doi: 10.1097/FJC.0000000000001677.
    

    >> Share

    
    January 2025
11. DIMITRIADIS K, Pitsiori D, Alexiou P, Pyrpyris N, et al
    Modulating Sympathetic Nervous System With the Use of SGLT2 Inhibitors: Where There Is Smoke, There Is Fire?
    J Cardiovasc Pharmacol. 2025;85:12-20.
    

    >> Share

    
    December 2024
12. KEFER E, Gulbis B, Weeks P
    Comparison of Urine Output Response of Intravenous Bumetanide and Furosemide in Acute Decompensated Heart Failure: an observational analysis.
    J Cardiovasc Pharmacol. 2024 Dec 5. doi: 10.1097/FJC.0000000000001658.
    

    >> Share

    
    November 2024
13. DENICOLAI M, Morello M, Golino M, Corna G, et al
    Interleukin-1 Blockade in Patients With ST-Segment Elevation Myocardial Infarction Across the Spectrum of Coronary Artery Disease Complexity.
    J Cardiovasc Pharmacol. 2024 Nov 12. doi: 10.1097/FJC.0000000000001652.
    

    >> Share

    
    September 2024
14. RYUNO Y, Kobayashi JI, Fujimoto Y, Dotare T, et al
    Effect of an Enteral Formula Enriched with omega-3 Fatty Acids, Carnitine, and Vitamin D on Body Weight, Heart Weight, and Blood Biochemical Parameters in a Dahl Rat Heart Failure Model.
    J Cardiovasc Pharmacol. 2024 Sep 26. doi: 10.1097/FJC.0000000000001637.
    

    >> Share

    
    
15. BIONDI-ZOCCAI G, Galli M, Booz GW
    Finerenone Proves Beneficial for Heart Failure with Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2024 Sep 26. doi: 10.1097/FJC.0000000000001636.
    

    >> Share

    
    
16. BIONDI-ZOCCAI G, Frati G, Peruzzi M, Booz GW, et al
    Empagliflozin: Primus Inter Pares Among Sodium-Glucose Cotransporter-2 Inhibitors?
    J Cardiovasc Pharmacol. 2024;84:271-275.
    

    >> Share

    
    
17. HAJIQASEMI M, Ebrahimzade M, Ghelichkhan ZA, Huang X, et al
    Ivabradine Approved and Other Uses in Clinical Practice: A Systematic Review.
    J Cardiovasc Pharmacol. 2024;84:276-288.
    

    >> Share

    
    August 2024
18. HENSON BD, Bale-Neary CA, Mecaskey R, Gbujie O, et al
    SGLT2 Inhibitors, Malnutrition, Cachexia, and Survival in Heart Failure Patients with a History of Anthracycline Treatment.
    J Cardiovasc Pharmacol. 2024 Aug 7. doi: 10.1097/FJC.0000000000001620.
    

    >> Share

    
    
19. GIBSON CM, Beard MM, Escano AK, Good BL, et al
    Metolazone vs chlorothiazide in acute heart failure patients with diuretic resistance and renal dysfunction: a retrospective cohort study.
    J Cardiovasc Pharmacol. 2024 Aug 7. doi: 10.1097/FJC.0000000000001623.
    

    >> Share

    
    July 2024
20. LINGYAN Z, Zijia H, Ya Z, Ying Z, et al
    Cardiovascular outcomes of SGLT-2 Inhibitors Across BMI Spectrum in Heart Failure Patients: An Updated Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2024 Jul 8. doi: 10.1097/FJC.0000000000001610.
    

    >> Share

    
    
21. ZHANG X, Sun G, Li Z, Gao W, et al
    Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Acute Myocardial Infarction With or Without Type 2 Diabetes: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2024;84:18-25.
    

    >> Share

    
    
22. LIU TH, Hsieh RJ, Chen HH, Kuo TJ, et al
    Propranolol Alleviates Cardiac Injury After Acute Catecholamine Infusion Through p38-MAPK Pathways.
    J Cardiovasc Pharmacol. 2024;84:110-117.
    

    >> Share

    
    May 2024
23. HOU B, Yu D, Bai H, Du X, et al
    Research progress of miRNA in heart failure: prediction and treatment.
    J Cardiovasc Pharmacol. 2024 May 3. doi: 10.1097/FJC.0000000000001588.
    

    >> Share

    
    April 2024
24. BARBIERO R, Pennella B, Bonaventura A
    The long-standing search for albumin placement in acute heart failure.
    J Cardiovasc Pharmacol. 2024 Apr 24. doi: 10.1097/FJC.0000000000001580.
    

    >> Share

    
    
25. KAKZANOV Y, Sevilya Z, Goldman A, Cipok M, et al
    The Effect of SGLT2 Inhibitor Therapy on Endothelial Progenitor Cell Function in Patients with Heart Failure.
    J Cardiovasc Pharmacol. 2024 Apr 24. doi: 10.1097/FJC.0000000000001581.
    

    >> Share

    
    
26. POLLESELLO P
    Repetitive treatments with inotropes in advanced heart failure.
    J Cardiovasc Pharmacol. 2024 Apr 2. doi: 10.1097/FJC.0000000000001569.
    

    >> Share

    
    
27. 
    The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Erratum.
    J Cardiovasc Pharmacol. 2024;83:359.
    

    >> Share

    
    March 2024
28. ZHANG X, Wang Z, Zhang L, Zhao X, et al
    Comparative effectiveness and safety of intermittent, repeated or continuous use of levosimendan, milrinone, or dobutamine in patients with advanced heart failure: a network and single-arm meta-analysis.
    J Cardiovasc Pharmacol. 2024 Mar 25. doi: 10.1097/FJC.0000000000001561.
    

    >> Share

    
    
29. ZOHORI BAHRAMI HS, Hasselbalch RB, Soholm H, Thomsen JH, et al
    First-in-man trial of beta3-adrenoceptor agonist treatment in chronic heart failure - impact on diastolic function.
    J Cardiovasc Pharmacol. 2024 Mar 5. doi: 10.1097/FJC.0000000000001545.
    

    >> Share

    
    January 2024
30. HUANG Y, Zhou H, Fang C, Ma L, et al
    Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for Patients With Heart Failure in China.
    J Cardiovasc Pharmacol. 2024;83:86-92.
    

    >> Share

    
    December 2023
31. SCOMA CB, Lee DH, Money D, Eichelberger G, et al
    The Impact of Midodrine On Guideline-Directed Medical Therapy in Patients Admitted with Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2023 Dec 21. doi: 10.1097/FJC.0000000000001532.
    

    >> Share

    
    November 2023
32. SILVETTI S, Pollesello P, Belletti A
    Repeated levosimendan infusions in the management of advanced heart failure: review of the evidence and meta-analysis of the effect on mortality.
    J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001506.
    

    >> Share

    
    
33. SUN Q, Cui W, Zhang X, Tian Y, et al
    A Systematic Review and Meta-analysis of Renin-angiotensin Inhibitors and Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence after Atrial Fibrillation Ablation.
    J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001517.
    

    >> Share

    
    
34. LAI M, Lam JC, Radosevich JJ, Patanwala AE, et al
    Levels of Albumin and Impact on Loop Diuretic and Albumin Co-administration in Heart Failure (LILAC-HF).
    J Cardiovasc Pharmacol. 2023 Nov 17. doi: 10.1097/FJC.0000000000001513.
    

    >> Share

    
    
35. KOMMU S
    The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2023 Nov 15. doi: 10.1097/FJC.0000000000001511.
    

    >> Share

    
    
36. ZHANG X, Wang N, Fu P, An Y, et al
    Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating beta-Hydroxybutyrate-activated Citrate Synthase.
    J Cardiovasc Pharmacol. 2023;82:375-388.
    

    >> Share

    
    October 2023
37. CANTRELL AC, Zeng H, Chen JX
    The therapeutic potential of targeting ferroptosis in the treatment of mitochondrial cardiomyopathies and heart failure.
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001496.
    

    >> Share

    
    
38. JAFREE E, Del Buono MG, Canada JM, Carbone S, et al
    Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure.
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001497.
    

    >> Share

    
    
39. CAMILLI M, Ballacci F, Giordano F, Minotti G, et al
    Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Heart Failure in China: a new pillar in our pockets, but at what price?
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001498.
    

    >> Share

    
    September 2023
40. BUONPANE A, Biondi-Zoccai G, Versaci F
    Molecular insights on ischemic heart failure: from core genes to hearts.
    J Cardiovasc Pharmacol. 2023 Sep 26. doi: 10.1097/FJC.0000000000001486.
    

    >> Share

    
    
41. LIN L, Zicheng L, Shaohua G
    Post-acute myocardial infarction heart failure core genes and relevant signaling pathways.
    J Cardiovasc Pharmacol. 2023 Sep 6. doi: 10.1097/FJC.0000000000001481.
    

    >> Share

    
    
42. BROCKMOLLER J, Ivanoski S, Hundack L, Blohm JH, et al
    Clinical and hemodynamic improvement in pulmonary hypertension after switching to sacubitril/valsartan in heart failure patients with preserved ejection fraction.
    J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001477.
    

    >> Share

    
    
43. PITT B, Rosenson RS
    Statins in patients with established heart failure: Time for reflection.
    J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001475.
    

    >> Share

    
    July 2023
44. PARK S, Chang J, Hong SP, Jin ES, et al
    Impact of Trimetazidine on the Incident Heart Failure Following Coronary Artery Revascularization.
    J Cardiovasc Pharmacol. 2023 Jul 11. doi: 10.1097/FJC.0000000000001453.
    

    >> Share

    
    June 2023
45. HU WS, Lin CL
    Angiotensin receptor-neprilysin inhibitor versus renin-angiotensin system inhibitor for dementia risk in patients with heart failure.
    J Cardiovasc Pharmacol. 2023 Jun 30. doi: 10.1097/FJC.0000000000001451.
    

    >> Share

    
    
46. AHMAD F, Karim A, Khan J, Qaisar R, et al
    Statin therapy induces gut leakage and neuromuscular disjunction in patients with chronic heart failure.
    J Cardiovasc Pharmacol. 2023 Jun 27. doi: 10.1097/FJC.0000000000001445.
    

    >> Share

    
    
47. MANILALL A, Mokotedi L, Gunter S, Le Roux R, et al
    Tumor Necrosis Factor-alpha Mediates Inflammation-induced Early-Stage Left Ventricular Systolic Dysfunction.
    J Cardiovasc Pharmacol. 2023;81:411-422.
    

    >> Share

    
    May 2023
48. AUGUSTIN N, Alvarez C, Kluger J
    The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
    J Cardiovasc Pharmacol. 2023 May 26. doi: 10.1097/FJC.0000000000001439.
    

    >> Share

    
    April 2023
49. HU WS, Lin CL
    Association of heart failure patients with and without sacubitril-valsartan use with incident cancer risk.
    J Cardiovasc Pharmacol. 2023 Apr 28. doi: 10.1097/FJC.0000000000001433.
    

    >> Share

    
    
50. NAKATANI D, Dohi T, Hikoso S, Tanaka A, et al
    Relationship between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients with Diabetes and Mild Heart Failure: Results from the CANDLE trial.
    J Cardiovasc Pharmacol. 2023 Apr 18. doi: 10.1097/FJC.0000000000001430.
    

    >> Share

    
    March 2023
51. ZHANG H, Huetteman AT, Reyes EA, Appelbaum JS, et al
    Effects of sacubitril-valsartan in Patients with Various Types of Heart Failure: A Meta-Analysis.
    J Cardiovasc Pharmacol. 2023 Mar 31. doi: 10.1097/FJC.0000000000001421.
    

    >> Share

    
    
52. KUANG N, Shu B, Yang F, Li S, et al
    TRAIL or TRAIL-R2 as a predictive biomarker for mortality or cardiovascular events: A systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2023 Mar 9. doi: 10.1097/FJC.0000000000001415.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share